Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Thursday

Sagimet Biosciences (NASDAQ:SGMT) is expected to issue its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 20, 2025 at 9:30 AM ET.

Sagimet Biosciences (NASDAQ:SGMT) last posted its earnings results on Wednesday, August 13th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.20. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sagimet Biosciences Stock Up 2.0%

Sagimet Biosciences stock opened at $8.50 on Wednesday. Sagimet Biosciences has a 52-week low of $1.73 and a 52-week high of $11.41. The firm’s fifty day moving average is $7.44 and its 200 day moving average is $7.03. The company has a market cap of $276.42 million, a price-to-earnings ratio of -4.64 and a beta of 3.26.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SGMT. Bank of America Corp DE boosted its position in Sagimet Biosciences by 81.8% in the 2nd quarter. Bank of America Corp DE now owns 9,943 shares of the company’s stock valued at $76,000 after buying an additional 4,473 shares during the period. XTX Topco Ltd increased its position in shares of Sagimet Biosciences by 137.0% during the second quarter. XTX Topco Ltd now owns 25,624 shares of the company’s stock worth $195,000 after acquiring an additional 14,813 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Sagimet Biosciences by 9,168.2% during the second quarter. BNP Paribas Financial Markets now owns 26,785 shares of the company’s stock valued at $204,000 after acquiring an additional 26,496 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Sagimet Biosciences in the first quarter valued at approximately $105,000. Finally, American Century Companies Inc. grew its stake in Sagimet Biosciences by 8.9% in the second quarter. American Century Companies Inc. now owns 42,285 shares of the company’s stock worth $322,000 after purchasing an additional 3,454 shares in the last quarter. Hedge funds and other institutional investors own 87.86% of the company’s stock.

Analysts Set New Price Targets

SGMT has been the subject of a number of analyst reports. Zacks Research raised shares of Sagimet Biosciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. Wedbush initiated coverage on Sagimet Biosciences in a research note on Monday, August 11th. They issued an “outperform” rating and a $28.00 price objective for the company. Wall Street Zen upgraded Sagimet Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, October 19th. Canaccord Genuity Group restated a “buy” rating and set a $28.00 price target on shares of Sagimet Biosciences in a report on Thursday, October 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Sagimet Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $28.40.

About Sagimet Biosciences

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.